Bisphosphonates and atypical femoral fractures

New England Journal of Medicine

Volumn 363, Issue 11, 2010, Pages 1084-

  Hofbauer, Lorenz C ^a   Jakob, Franz ^b   Felsenberg, Dieter ^c  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; GLUCOCORTICOID;

BONE NECROSIS; DIABETES MELLITUS; DRUG USE; FEMUR FRACTURE; GENETIC RISK; HUMAN; LETTER; LONG TERM CARE; OSTEOLYSIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK FACTOR;

BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; BONE RESORPTION; DIPHOSPHONATES; FEMORAL FRACTURES; HUMANS; OSTEONECROSIS; RISK FACTORS;

EID: 77956525002     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (4)

1. Girgis CM, Sher D, Seibel MJ. Atypical femoral fractures and bisphosphonate use. N Engl J Med 2010;362:1848-9.
2. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-91.
3. Roelofs AJ, Coxon FP, Ebetino FH, et al. Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. J Bone Miner Res 2010;25:606-16.
4. Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 2010;95:1555-65.